Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134731 · ClinicalTrials.gov registry record · Phase 4
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT01134731 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 54 participants.
The verdict
NCT01134731, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary objective is a clinical trial to compare the efficacy of paliperidone versus lithium and placebo as adjunctive therapy to the standard of care antidepressants in the acute management of suicidality in depressed subjects. Specific Aims 1 and 2 are described in detail below. Analysis for Specific Aim 2 is still underway.
Interventions
- DRUG Placebo
- DRUG paliperidone
- DRUG lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134731
The ClinicalTrials.gov registry entry for NCT01134731 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01134731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134731 about?
NCT01134731 is a clinical study titled "Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation". The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary objective is a clinical trial to compare the efficacy of paliperidone versus l...
What is the current status of trial NCT01134731?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2010-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01134731?
The interventions under investigation include: Placebo (DRUG), paliperidone (DRUG), lithium (DRUG).
Who is sponsoring clinical trial NCT01134731?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.